NCT07036328

Transcranial Magnetic Stimulation to Slow Down Cognitive Decline in Alzheimer's Disease

Transcranial Magnetic Stimulation (TMS) to Slow Down Cognitive Decline in Alzheimer's Disease (AD): TMSLA - a Monocentric Randomized Controlled Trial.

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 62 (estimated)
• Sponsor: Willem de Haan · Academic / Other
• Sex: All
• Age: 50 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

New amyloid-targeting drugs for Alzheimer's disease (AD) offer minimal or unclear efficacy and often cause adverse events, highlighting the need for new therapies. In recent years, repetitive transcranial magnetic stimulation (rTMS) has shown increasing success. A recent randomized, double-blind, sham-controlled, phase 2 demonstrated promising results from a 24-week rTMS treatment protocol targeting the precuneus. This brain region is considered a main hub of the human brain connectome and a prominent area of AD pathology. The results showed stable cognitive performance and increased brain activity in the treatment group, whereas the sham group worsened. A replication study is planned to further investigate the working mechanism of precuneus-rTMS in AD and to improve understanding of its therapeutic potential.

Conditions

• Alzheimer Disease
• Alzheimer Disease, Early Onset

Interventions

Type	Name	Description
DEVICE	repetitive transcranial magnetic stimulation	20 Hz repetitive transcranial magnetic stimulation targeted at the precuneus
DEVICE	sham repetitive transcranial magnetic stimulation	20 Hz sham repetitive transcranial magnetic stimulation targeted at the precuneus

Timeline

• Start date: 2025-04-07
• Primary completion: 2028-01-01
• Completion: 2028-07-01
• First posted: 2025-06-25
• Last updated: 2025-06-25

Locations

1 site across 1 country: Netherlands